Schwarz' Neupro launched in the UK
German drugmaker Schwarz Pharma's dopamine agonist Neupro (rotigotine transdermal patch), has been launched in the UK for early-stage Parkinson's disease.
According to the Monheim-headquartered pharmaceutical firm, the agent's transdermal delivery system provides consistent and continuous drug delivery over 24 hours and eliminates the peaks and troughs in drug levels associated with oral treatment that can lead to fluctuations in symptom control. It adds that its once-daily dosing is likely to be more convenient than taking tablets several times a day.
Rotigotine, which has a similar receptor-binding profile to naturally-occurring dopamine, has been evaluated in more than 1,200 patients. The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on the agent in December 2005, and granted marketing authorization in February.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze